Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | VDR | P11473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3387782 | 0.86 | CYP2D6 (0.53) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL31628097 | 0.83 | CYP2D6 (0.49) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL3630570 | 0.79 | CYP2D6 (0.58) | CYP2D6CYP1A2L3MBTL1CYP3A4CYP2C19 | |
| SCHEMBL420300 | 0.78 | CYP2D6 (0.74) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL3388527 | 0.78 | CYP2D6 (0.74) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL28714858 | 0.77 | CYP2D6 (0.51) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL10597771 | 0.77 | CYP2D6 (0.50) | CYP2D6CYP1A2MCOLN3L3MBTL1CYP3A4 | |
| SCHEMBL657896 | 0.77 | CYP2D6 (0.67) | CYP2D6CYP1A2CYP3A4CYP2C19VDR | |
| SCHEMBL10376015 | 0.77 | CYP2D6 (0.67) | CYP2D6CYP1A2CYP3A4CYP2C19VDR | |
| SCHEMBL9703277 | 0.76 | CYP2D6 (0.63) | CYP2D6CYP1A2MCOLN3L3MBTL1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025128777-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | WO | disclosed |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | MERCK SHARP & DOHME LLC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-02-23 | — | — | US | disclosed |
| CN-110256418-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2023-01-20 | — | — | CN | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | BAYER AKTIENGESELLSCHAFT (DE) | 2021-10-12 | — | — | US | disclosed |
| EP-3230281-B1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AG (DE) | 2021-05-26 | — | — | EP | disclosed |
| CN-107207507-B | 1, 3-thiazol-2-yl substituted benzamides | 拜耳公司 | 2020-11-06 | — | — | CN | disclosed |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2018-05-03 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-04-05 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2018-03-15 | — | — | US | disclosed |
| EP-3230281-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | Bayer Aktiengesellschaft (DE) | 2017-10-18 | — | — | EP | disclosed |
| WO-2016091776-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | EVOTEC AG (DE) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093980-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
| US-20230053411-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
| US-20180118731-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
| US-20250195511-A1 | INDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF NOD-LIKE RECEPTOR PROTEIN 3 | NLRP3, FABP3, NOD1 | CYP2D6 1941/4885CYP1A2 2048/4885MCOLN3 169/4885 |
| US-11142523-B2 | 1,3-thiazol-2-yl substituted benzamides | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
| US-20180072713-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
| US-20200131169-A1 | 1,3-THIAZOL-2-YL SUBSTITUTED BENZAMIDES | NAT1, HNMT, PMP22 | CYP2D6 1296/4885CYP1A2 614/4885MCOLN3 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.